GB Sciences (GB Sciences) EPS (Basic) : $-0.01 (TTM As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is GB Sciences EPS (Basic)?

GB Sciences's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01.

GB Sciences's EPS (Diluted) for the three months ended in Dec. 2023 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01.

GB Sciences's EPS without NRI for the three months ended in Dec. 2023 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

GB Sciences EPS (Basic) Historical Data

The historical data trend for GB Sciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GB Sciences EPS (Basic) Chart

GB Sciences Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EPS (Basic)

Get a 7-Day Free Trial

-0.11

-0.05

-0.01

GB Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-	-0.01	-	-	-

GB Sciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

GB Sciences's Basic EPS for the fiscal year that ended in Mar. 2023 is calculated as

Basic EPS (A: Mar. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-4.125	-	0)	/	357.721
	=	-0.01

GB Sciences's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.187	-	0)	/	403.172
	=	-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

GB Sciences (OTCPK:GBLX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

GB Sciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of GB Sciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

GB Sciences (GB Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GB Sciences Inc (OTCPK:GBLX) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

18C:Germany

Address

9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148

Website

https://www.gbsciences.com

GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments.

Executives

John C Poss	director, officer: Chief Executive Officer
Craig Ellins	director, 10 percent owner, officer: CEO	3035 EAST PATRICK LANE, SUITE 9, LAS VEGAS NV 89120
Lazarus Management Co Llc	10 percent owner	260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Israel Opportunities Fund Lllp	10 percent owner	C/O IBEX GP LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Investment Partners Lllp	10 percent owner	C/O IBEX INVESTORS LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Justin B Borus	10 percent owner	260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206